Aurase Wound Gel
Chronic Wounds (e.g., Venous Leg Ulcers, Diabetic Foot Ulcers)
Phase 2Active
Key Facts
Indication
Chronic Wounds (e.g., Venous Leg Ulcers, Diabetic Foot Ulcers)
Phase
Phase 2
Status
Active
Company
About SolasCure
SolasCure is a clinical-stage biotech addressing the significant unmet need in chronic wound healing with its lead candidate, Aurase Wound Gel. The biologic has completed a second Phase II trial, demonstrating accelerated healing compared to standard care. The company has secured substantial non-dilutive grant funding from UK and EU bodies and is led by a team with deep wound care and biotech experience. SolasCure is positioned to advance a first-in-class therapeutic that combines continuous debridement with active stimulation of healing biology.
View full company profileTherapeutic Areas
Other Chronic Wounds (e.g., Venous Leg Ulcers, Diabetic Foot Ulcers) Drugs
| Drug | Company | Phase |
|---|---|---|
| AKR101 | Akribes Biomedical | Pre-clinical |